2014
DOI: 10.1155/2014/358567
|View full text |Cite
|
Sign up to set email alerts
|

Lung Sarcoidosis in Etanercept Treated Rheumatoid Arthritis Patient: A Case Report and Review of the Literature

Abstract: We report a 55-year-old female with seropositive rheumatoid arthritis for 10 years who developed large mediastinal and hilar adenopathy while receiving etanercept therapy. Chest high resolution computed tomography (HRCT) showed mediastinal lymph nodes with size of 2.3 × 3.1 centimeters. Right paratracheal lymph node biopsy showed nonnecrotizing epithelioid granulomata. All infectious studies of pulmonary lymph node tissues were negative. Etanercept was discontinued. Follow-up HRCT 6 months later showed resolut… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
4
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(4 citation statements)
references
References 15 publications
0
4
0
Order By: Relevance
“…Intriguingly, there have been many reported cases in which patients with RA developed sarcoidosis after anti-TNF-α administration. 27 , 28 Anti-TNF-α treatment-induced sarcoidosis and/or sarcoid-like reactions have also been reported in patients with psoriatic arthritis, 29 ankylosing spondylitis, 30 and inflammatory bowel diseases, 31 suggesting that the development of sarcoidosis is more likely to be associated with anti-TNF-α treatment than be due to the underlying disease. Indeed, in most cases, patients improve upon discontinuation of anti-TNF-α agents, with or without systemic corticosteroid use.…”
Section: Discussionmentioning
confidence: 99%
“…Intriguingly, there have been many reported cases in which patients with RA developed sarcoidosis after anti-TNF-α administration. 27 , 28 Anti-TNF-α treatment-induced sarcoidosis and/or sarcoid-like reactions have also been reported in patients with psoriatic arthritis, 29 ankylosing spondylitis, 30 and inflammatory bowel diseases, 31 suggesting that the development of sarcoidosis is more likely to be associated with anti-TNF-α treatment than be due to the underlying disease. Indeed, in most cases, patients improve upon discontinuation of anti-TNF-α agents, with or without systemic corticosteroid use.…”
Section: Discussionmentioning
confidence: 99%
“…7 On the other hand, infliximab, an anti-TNF-a monoclonal antibody, has been shown to be effective in the treatment of pulmonary sarcoidosis while etanercept, a soluble TNF-a receptor fusion protein, has not. 3 Moreover, in a study including 17 patients with pulmonary sarcoidosis, etanercept treatment was found to be associated with aggravation of the disease. 8 In this article, we report an AS patient who was diagnosed as sarcoidosis during the period of etanercept usage.…”
mentioning
confidence: 99%
“…1,2 However, granulomatous conditions such as sarcoidosis have scarcely been reported in the literature. 3 The frequency of this adverse effect has been reported as 0.04% (1/2800). 4 Etanercept is the most frequently mentioned agent followed by infliximab and adalimumab.…”
mentioning
confidence: 99%
See 1 more Smart Citation